Xylem Expands Partnership with Imagine H2O to Support Water Innovation Entrepreneurs

Global Partnership Scales Imagine H2O’s Work with Entrepreneurial Water Solutions RYE BROOK, N.Y.–(BUSINESS WIRE)–Oct. 21, 2021– Xylem Inc. (NYSE: XYL), a leading global water technology company dedicated to solving the world’s greatest water challenges has announced an expanded commitment to Imagine H2O, the leading water innovation accelerator and ecosystem for water entrepreneurs. As a global... Read more

PerkinElmer Participates in NIST Program to Advance Cannabis and Hemp Testing Standardization

Company’s Work with Federal organization focused on heavy metals and cannabinoid analysis aimed at helping labs and producers meet key regulations more effectively and efficiently October 19, 2021 WHAT : PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced its participation in the National Institute of Standards and Technology’s (NIST)... Read more

Clear Labs Automated NGS Technology Platform (Clear Safety™) Approved by USDA’s National Poultry Improvement Plan for Salmonella Detection

Leader in Next-Generation Sequencing Workflow Automation Gains Agency Accreditation for Animal Health Testing SAN CARLOS, CALIF. (PRWEB) OCTOBER 14, 2021 Today, Clear Labs, a leader in providing fully automated, next-generation sequencing (NGS) platforms for turnkey diagnostics, is announcing that Clear Safety Salmonella has been approved by the National Poultry Improvement Plan (NPIP) for interim use in the detection of... Read more

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

SANTA CLARA, Calif., October 13, 2021  Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered.... Read more

Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis

35% reduction in risk of needing a walking aid in relapsing multiple sclerosis (RMS) after 7.5 years vs. initiation 2 years later in Phase III open-label extension (OLE) 29% reduction in 48-week confirmed disability progression in primary progressive MS (PPMS) after 8 years vs. initiation after double-blind period in Phase III OLE New 8-year safety... Read more

On Everyone’s Lips: Microplastics

Scientists are rushing to study the tiny plastic particles that are in marine animals — and in us. The distribution of microplastics into the world is extensive; however, the implications of microplastics are not yet thoroughly understood. Dr. Elke Fischer from the Department of Earth Sciences of the University of Hamburg is providing compelling insights... Read more

Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021

OCREVUS (ocrelizumab) data to show sustained reduction in disability progression through 8 years for primary progressive multiple sclerosis (PPMS) and 7.5 years for relapsing MS (RMS) Long-term safety analysis of all clinical trials will reinforce the consistently favourable benefit-risk profile of OCREVUS ENSPRYNG (satralizumab) data to show efficacy and safety sustained over four years of... Read more

Xylem, Dragos Partner to Bring Cybersecurity Leadership to Water Utilities

RYE BROOK, N.Y.–(BUSINESS WIRE)–Oct. 4, 2021– Leading global water technology company, Xylem Inc., and Dragos, Inc., the global leader in cybersecurity for industrial controls systems (ICS)/operational technology (OT) environments, today announced they have partnered to bring best-in-class industrial cybersecurity to critical infrastructure in the water sector. The agreement will see Xylem and Dragos offering co-branded... Read more

Xylem Reaffirms Growth Strategy and Digital Leadership at 2021 Investor Day

Provides Long-term Financial Framework and Updates Current Year Outlook RYE BROOK, NY–(BUSINESS WIRE)–Sep. 30, 2021– Global water technology company, Xylem (NYSE:XYL), will reaffirm its growth strategy and set out its long-term financial framework at its Investor Day, to be held today. Xylem President and CEO Patrick Decker, along with other senior leaders, will provide an... Read more